Literature DB >> 11859424

Genetic immunization with a melanocytic self-antigen linked to foreign helper sequences breaks tolerance and induces autoimmunity and tumor immunity.

J Steitz1, J Brück, A Gambotto, J Knop, T Tüting.   

Abstract

Mechanisms maintaining peripheral tolerance to self-antigens present a major obstacle for the development of antigen-specific melanoma vaccines, presumably because self-antigens are not able to stimulate a CD4 T-helper response. Using the melanosomal enzyme tyrosinase-related protein 2 (TRP2) expressed by melanocytes and most melanoma cells as a model self-antigen, we investigated whether linkage with a foreign immunogenic protein providing strong CD4 helper sequences would be able to circumvent tolerance and enhance the induction of antigen-specific tumor immunity. We found that genetic immunization of mice with cDNA encoding a fusion protein between enhanced green fluorescent protein (EGFP) from jellyfish and autologous murine TRP2 (EGFP.mTRP2) resulted in the stimulation of TRP2-reactive T cells in vivo. Importantly, immunization with EGFP.mTRP2 effectively protected mice against metastatic growth of B16 melanoma in the lungs and was associated with fur depigmentation as a sign of autoimmune-mediated destruction of melanocytes. Our results show that tumor vaccines consisting of self-antigens linked to immunogenic helper sequences can be successfully applied to the immunotherapy of melanoma and provide a scientific basis for the translation of this strategy in future clinical investigations.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11859424     DOI: 10.1038/sj.gt.3301634

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  7 in total

1.  Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine.

Authors:  Basav N Hangalapura; Dinja Oosterhoff; Tarun Gupta; Jan de Groot; Pepijn G J T B Wijnands; Victor W van Beusechem; Joke den Haan; Thomas Tüting; Alfons J M van den Eertwegh; David T Curiel; Rik J Scheper; Tanja D de Gruijl
Journal:  Vaccine       Date:  2011-01-25       Impact factor: 3.641

2.  Rapid growth of invasive metastatic melanoma in carcinogen-treated hepatocyte growth factor/scatter factor-transgenic mice carrying an oncogenic CDK4 mutation.

Authors:  Damia Tormo; Aleix Ferrer; Evelyn Gaffal; Jörg Wenzel; Etiena Basner-Tschakarjan; Julia Steitz; Lukas C Heukamp; Ines Gütgemann; Reinhard Buettner; Marcos Malumbres; Mariano Barbacid; Glenn Merlino; Thomas Tüting
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

3.  Ubiquitin-fusion degradation pathway plays an indispensable role in naked DNA vaccination with a chimeric gene encoding a syngeneic cytotoxic T lymphocyte epitope of melanocyte and green fluorescent protein.

Authors:  Manxin Zhang; Kazunari Ishii; Hajime Hisaeda; Shigeo Murata; Tomoki Chiba; Keiji Tanaka; Yang Li; Chikage Obata; Masutaka Furue; Kunisuke Himeno
Journal:  Immunology       Date:  2004-08       Impact factor: 7.397

4.  Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity.

Authors:  Jeanette E Boudreau; Byram W Bridle; Kyle B Stephenson; Kristina M Jenkins; Jérôme Brunellière; Jonathan L Bramson; Brian D Lichty; Yonghong Wan
Journal:  Mol Ther       Date:  2009-04-28       Impact factor: 11.454

5.  Control of human mesothelin-expressing tumors by DNA vaccines.

Authors:  C-L Chang; T-C Wu; C-F Hung
Journal:  Gene Ther       Date:  2007-06-21       Impact factor: 5.250

6.  T-Cell Mediated Immune Responses Induced in ret Transgenic Mouse Model of Malignant Melanoma.

Authors:  Oliver Abschuetz; Wolfram Osen; Kathrin Frank; Masashi Kato; Dirk Schadendorf; Viktor Umansky
Journal:  Cancers (Basel)       Date:  2012-04-26       Impact factor: 6.639

7.  Quantification of B16 melanoma cells in lungs using triplex Q-PCR--a new approach to evaluate melanoma cell metastasis and tumor control.

Authors:  Maria R Sorensen; Sara R Pedersen; Annika Lindkvist; Jan P Christensen; Allan R Thomsen
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.